Home
Categories
Ingredients
Analysis
Manufacturing
Finance
Regulatory
Drug Delivery
Research & Development
Sustainability
Pharma 5.0
Company News
Events
Directory
Search
Close search
Home
Company
Pharmexcil
Pharmexcil
X
LinkedIn
Trending Articles
Agilent boosts contract manufacturing capabilities with acquisition of BIOVECTRA
The CDMO acquisition will bolster Agilent's end-to-end production capabilities in a number of popular therapeutics, including GLP-1 medications and ADCs
Therapeutic: ensifentrine for chronic obstructive pulmonary disease
Chronic obstructive pulmonary disease (COPD) comes in various guises, including chronic bronchitis and emphysema; and, although incurable, the symptoms can be managed with...
Merck’s clesrovimab meets all primary endpoints in Phase IIb/III trial for RSV in infants
A teaser of the Phase IIb/III trial released by Merck indicates that clesrovimab can reduce the need to medically attend lower respiratory infections caused by RSV in infants
Bringing biotech to the Baltics: the rise of Lithuania
Lithuania’s biotechnology competencies lie in cell and gene therapies, enzymes and the wider pharmaceutical industry, offering companies a rich pool of talent in a...
Currax to build novel anti-obesity treatment production facility amidst GLP-1 supply issues
The manufacturing facility will be dedicated to the production of anti-obesity drug Contrave, and will double its output in the EU and EEA
Upcoming event
ISPE Singapore
28-30 August 2024 | Conference and exhibition | Singapore
See all
Related Content
Manufacturing
Contract manufacturing in India grows at 20%
SMEs predicted to be main beneficiaries of this growth
India calls off EU trade talks
Action reflects disappointment at EU ban on 700 Indian-made generics
Pharmaceutical
India and China set to dominate biosimilars market
Annual growth rate for biosimilars in India and China could reach 30% in 2014-18
Regulatory obstacles hinder Indian pharma exports to Vietnam
Companies 'red listed' by Vietnamese drug regulatory authority for regulatory non-compliance
Indian pharma exports could miss growth target
Delays in regulatory approvals in North America could halve expected growth rate
Pharmaceutical
Indian pharma to target eastern Europe
Delegation set to promote generics in Hungary, Czech Republic and Romania
Finance
India pharma exports to touch $25bn by 2018
Ability to supply Argentina a major boost to export growth
Subscribe now